Chiasma (NASDAQ:CHMA) announces 48-week data from the open-label extension (OLE) from the Phase 3 OPTIMAL trial evaluating Mycapssa (octreotide) in acromegaly patients.
In patients that completed the 36-week randomized trial and responded to treatment, insulin-like growth factor 1 (IGF-1) levels were maintained within normal limits for an additional 48 weeks (IGF-1 is elevated in the growth hormonal disorder).
No new safety signals were observed.
The OLE is ongoing.
The FDA approved Mycapssa for acromegaly on June 26.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.